TERT promoter mutations and telomere length in adult malignant gliomas and recurrences.
(2015) In Oncotarget 6(12). p.10617-10633- Abstract
- In this report on 303 gliomas we show the highest frequency of TERT promoter mutations in gliobastomas (80%) followed by oligodendrogliomas (70%) and astrocytomas (39%). We observed positive association between TERT promoter and IDH mutations in oligodendroglial tumors (OR = 26.3; 95% CI 2.5-250.2) and inverse association in primary glioblastomas (OR = 0.13; 95% CI 0.03-0.58). Tumors with TERT promoter mutations compared to those without showed increased TERT transcription; we also showed difference in the transcription levels due to the two main mutations. Tumors with TERT promoter mutations had shorter telomeres than those without. The patients with only TERT promoter mutations showed worst survival (median survival 14.6 months) and... (More)
- In this report on 303 gliomas we show the highest frequency of TERT promoter mutations in gliobastomas (80%) followed by oligodendrogliomas (70%) and astrocytomas (39%). We observed positive association between TERT promoter and IDH mutations in oligodendroglial tumors (OR = 26.3; 95% CI 2.5-250.2) and inverse association in primary glioblastomas (OR = 0.13; 95% CI 0.03-0.58). Tumors with TERT promoter mutations compared to those without showed increased TERT transcription; we also showed difference in the transcription levels due to the two main mutations. Tumors with TERT promoter mutations had shorter telomeres than those without. The patients with only TERT promoter mutations showed worst survival (median survival 14.6 months) and patients with both IDH and TERT promoter mutations showed best survival (246.5 months). In patients with astrocytoma, the TERT promoter mutations only associated with poor survival (P < 0.0001); IDH mutations and 1p/19q deletions associated with increased survival (P = 0.0004). TERT promoter mutations in low grade gliomas associated with reduced progression free survival (HR 10.2; 95% CI 1.9 - 55.9). While our data affirm the role of TERT promoter mutations in glial tumors, effects on transcription and telomere length emphasise the importance of telomere biology in disease genesis and outcome. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/5257878
- author
- Heidenreich, Barbara ; Rachakonda, P Sivaramakrishna ; Hosen, Ismail ; Volz, Florian ; Hemminki, Kari LU ; Weyerbrock, Astrid and Kumar, Rajiv
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Oncotarget
- volume
- 6
- issue
- 12
- pages
- 10617 - 10633
- publisher
- Impact Journals
- external identifiers
-
- pmid:25797251
- wos:000358874600074
- scopus:84929600818
- ISSN
- 1949-2553
- language
- English
- LU publication?
- yes
- id
- 98b58181-8d57-4061-a8fc-cec68fe51d70 (old id 5257878)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/25797251?dopt=Abstract
- date added to LUP
- 2016-04-01 13:39:13
- date last changed
- 2022-04-21 22:48:02
@article{98b58181-8d57-4061-a8fc-cec68fe51d70, abstract = {{In this report on 303 gliomas we show the highest frequency of TERT promoter mutations in gliobastomas (80%) followed by oligodendrogliomas (70%) and astrocytomas (39%). We observed positive association between TERT promoter and IDH mutations in oligodendroglial tumors (OR = 26.3; 95% CI 2.5-250.2) and inverse association in primary glioblastomas (OR = 0.13; 95% CI 0.03-0.58). Tumors with TERT promoter mutations compared to those without showed increased TERT transcription; we also showed difference in the transcription levels due to the two main mutations. Tumors with TERT promoter mutations had shorter telomeres than those without. The patients with only TERT promoter mutations showed worst survival (median survival 14.6 months) and patients with both IDH and TERT promoter mutations showed best survival (246.5 months). In patients with astrocytoma, the TERT promoter mutations only associated with poor survival (P < 0.0001); IDH mutations and 1p/19q deletions associated with increased survival (P = 0.0004). TERT promoter mutations in low grade gliomas associated with reduced progression free survival (HR 10.2; 95% CI 1.9 - 55.9). While our data affirm the role of TERT promoter mutations in glial tumors, effects on transcription and telomere length emphasise the importance of telomere biology in disease genesis and outcome.}}, author = {{Heidenreich, Barbara and Rachakonda, P Sivaramakrishna and Hosen, Ismail and Volz, Florian and Hemminki, Kari and Weyerbrock, Astrid and Kumar, Rajiv}}, issn = {{1949-2553}}, language = {{eng}}, number = {{12}}, pages = {{10617--10633}}, publisher = {{Impact Journals}}, series = {{Oncotarget}}, title = {{TERT promoter mutations and telomere length in adult malignant gliomas and recurrences.}}, url = {{https://lup.lub.lu.se/search/files/3501505/8234266.pdf}}, volume = {{6}}, year = {{2015}}, }